
Evidence analysis
Pancreatic cancer: The RAS paradigm shift
Pancreatic Cancer: The RAS Paradigm Shift - An Evidence Dossier Source: PLOS Medicine, article published October 29, 2026, by Samuel P. Soff and Eileen M. O’Reilly What is Established Pancreatic ductal adenocarcinoma (PDAC) is recognized as one of…
Read →
Evidence analysis
Immunogenicity and safety of Institut Pasteur du Cambodge (IPC) and updated Thai Red Cross (UTRC) intradermal rabies vaccine regimens among healthy adults in India: A phase 4, open label, equivalence randomised controlled trial
Immunogenicity and Safety of Shorter Intradermal Rabies Vaccine Regimens in India: Evidence from a Phase 4 Trial Rabies remains a fatal viral disease with significant public health impact worldwide, especially in India, which bears a large proportion of…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Opdivo, nivolumab, Date of authorisation: 19/06/2015, Revision: 77, Status: Authorised
Opdivo (Nivolumab) - European Public Assessment Report Evidence Dossier What is established Opdivo, whose active substance is nivolumab, is an immune checkpoint inhibitor authorized by the European Medicines Agency (EMA) for the treatment of several advanced cancers. Opdivo…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron), dinutuximab beta, Date of authorisation: 08/05/2017, Revision: 19, Status: Authorised
Qarziba (Dinutuximab beta) for Neuroblastoma: An Evidence Dossier What is established Qarziba is a medicinal treatment authorised in the European Union for the management of neuroblastoma, a cancer of nerve cells primarily affecting children older than one year.…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Carvykti, ciltacabtagene autoleucel, Date of authorisation: 25/05/2022, Revision: 19, Status: Authorised
What is established Carvykti (ciltacabtagene autoleucel) is a genetically engineered therapy approved in the European Union for the treatment of multiple myeloma, a type of bone marrow cancer. It is authorized for adult patients whose disease has relapsed…
Read →
Evidence analysis
How IRL Story Lab is Reimagining What Journalism Can Do
Investigative Reporting Lab Turns Journalism Into Award-Winning Fiction to Engage New Audiences What is established The Investigative Reporting Lab (IRL), a North Macedonian media and member of the Organized Crime and Corruption Reporting Project (OCCRP), has launched an…
Read →
Evidence analysis
First public health emergency preparedness assessments across Europe show both commitment and recurring challenges
Evidence Dossier: Public Health Emergency Preparedness in Europe What is established The European Centre for Disease Prevention and Control (ECDC), in collaboration with the European Commission, the World Health Organization (WHO) Regional Office for Europe, and other partners,…
Read →
Evidence analysis
Challenges and recommendations for implementation of oncology clinical practice guidelines in China
Challenges and Recommendations for Implementation of Oncology Clinical Practice Guidelines in China What is established Cancer remains a leading public health challenge in China, contributing to roughly a quarter of the global cancer cases and deaths. The rapid…
Read →
Evidence analysis
Notice to sponsors on validation and qualification of computerised systems used in clinical trials
Notice to sponsors on validation and qualification of computerised systems used in clinical trials Date: 28 October 2026 What is established Validation and qualification of computerised systems are critical components in the conduct of clinical trials to ensure…
Read →
Evidence analysis
Veterinary medicines European public assessment report (EPAR): Cirbloc, porcine circovirus vaccine (inactivated), Status: Authorised
Health & Science Evidence Dossier: Cirbloc Porcine Circovirus Vaccine (Inactivated) What is established The European Medicines Agency (EMA) has authorised a veterinary medicinal product named Cirbloc, which is an inactivated vaccine developed to protect pigs against porcine circovirus…
Read →